Literature DB >> 15596731

A multimodal approach to managing the symptoms of multiple sclerosis.

Heidi Crayton1, Rock A Heyman, Howard S Rossman.   

Abstract

Multiple sclerosis (MS) is a disease of the CNS with a challenging clinical course characterized by heterogeneous symptoms related to inflammation and demyelination. Disease-modifying agents (DMAs) are used to treat the related neuronal degradation. Certain symptoms occur regularly, although with variable frequency, regardless of treatment with DMAs. Because there is no cure for MS at this time, symptom management is critically important to quality of life. Symptoms commonly seen are spasticity, fatigue, sexual dysfunction, bladder dysfunction, pain, and cognitive dysfunction. Other symptoms include depression, bowel dysfunction, paroxysmal symptoms, and weakness. The symptom management model that provides optimal results for patients with MS is a multimodal approach using effective communication, patient education, physical modalities and activities, occupational and other therapies, and pharmacologic interventions. Individualizing treatment for each patient involves gaining control of symptoms as early as possible to prevent cycles of symptoms from developing.

Entities:  

Mesh:

Year:  2004        PMID: 15596731     DOI: 10.1212/wnl.63.11_suppl_5.s12

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

1.  Topiramate therapy for symptomatic trigeminal neuralgia.

Authors:  A Siniscalchi; L Gallelli; D Scornaienghi; F Mancuso; G De Sarro
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 2.  Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis.

Authors:  Federica Puccini; Alka Bhide; Suzy Elneil; G Alessandro Digesu
Journal:  Int Urogynecol J       Date:  2015-07-09       Impact factor: 2.894

3.  Value, challenges, and satisfaction of certification for multiple sclerosis specialists.

Authors:  Elsie E Gulick; June Halper
Journal:  Int J MS Care       Date:  2014

4.  Sleep disorders in patients with multiple sclerosis in China.

Authors:  Shengli Ma; Xue Rui; Peiyi Qi; Gangqiong Liu; Jing Yang
Journal:  Sleep Breath       Date:  2016-10-11       Impact factor: 2.816

Review 5.  The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review.

Authors:  A Tubaro; F Puccini; C De Nunzio; G A Digesu; S Elneil; C Gobbi; V Khullar
Journal:  Curr Urol Rep       Date:  2012-10       Impact factor: 3.092

6.  The prevalence of urinary catheterization in women and men with multiple sclerosis.

Authors:  Sangeeta T Mahajan; Heidi E Frasure; Ruth Ann Marrie
Journal:  J Spinal Cord Med       Date:  2013-04-12       Impact factor: 1.985

7.  Low Prevalence of Sleep Disorders in Demyelinating Disease in a Northern Tenerife Population.

Authors:  Montserrat González-Platas; Javier González-Platas; Moises Bermúdez-Hernández; Maria Yaiza Pérez-Martín; Cristina Croissier-Elías; Pedro Javier Pérez-Lorensu
Journal:  J Clin Sleep Med       Date:  2016-06-15       Impact factor: 4.062

8.  Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.

Authors:  Lanting Lu; Hilary Pearce; Chris Roome; James Shearer; Iain A Lang; Ken Stein
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

9.  The contribution of cognition and spasticity to driving performance in multiple sclerosis.

Authors:  Thomas D Marcotte; Theodore J Rosenthal; Erica Roberts; Sara Lampinen; J Cobb Scott; R Wade Allen; Jody Corey-Bloom
Journal:  Arch Phys Med Rehabil       Date:  2008-09       Impact factor: 3.966

10.  Sonographic basal ganglia alterations are related to non-motor symptoms in multiple sclerosis.

Authors:  Sebastian Horowski; Uwe K Zettl; Reiner Benecke; Uwe Walter
Journal:  J Neurol       Date:  2010-08-26       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.